Empagliflozin/linagliptin

Empagliflozin/linagliptin

Combination of
Empagliflozin	SGLT2 inhibitor
Linagliptin	DPP-4 inhibitor
Clinical data
Trade names	Glyxambi
AHFS/Drugs.com	Professional Drug Facts
License data	EU EMA: by INN US DailyMed: Glyxambi US FDA: Glyxambi
Pregnancy category	AU: D
Routes of administration	By mouth
ATC code	A10BD19 (WHO)
Legal status
Legal status	AU: UK: POM (Prescription only) US: ℞-only EU: Rx-only In general: ℞ (Prescription only)
Identifiers
CAS Number	864070-44-0 Y 668270-12-0 Y
PubChem CID	85364159
UNII	HDC1R2M35U 3X29ZEJ4R2 Y
KEGG	D10588 Y
Chemical and physical data
Formula	C48H55ClN8O9
Molar mass	923.47 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC#CCN1C2=C(N=C1N3CCCC(C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C.COC1C(C(C(C(O1)C2=CC(=C(C=C2)Cl)CC3=CC=C(C=C3)OC4CCOC4)O)O)O
InChI InChI=1S/C25H28N8O2.C23H27ClO7/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20;1-28-23-21(27)19(25)20(26)22(31-23)14-4-7-18(24)15(11-14)10-13-2-5-16(6-3-13)30-17-8-9-29-12-17/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3;2-7,11,17,19-23,25-27H,8-10,12H2,1H3/t17-;17-,19+,20+,21-,22-,23-/m10/s1 Key:POMOOZUJAXCEKG-QPVQWCQSSA-N
(verify)

Empagliflozin/linagliptin, sold under the brand name Glyxambi, is a fixed-dose combination anti-diabetic medication used to treat type 2 diabetes. It is a combination of empagliflozin and linagliptin. It is taken by mouth.

The most common side effects include urinary infections, nasopharyngitis, and upper respiratory tract infections .

It was approved for use in the United States in January 2015, for use in the European Union in November 2016, and for use in Australia in December 2016.

Medical uses

In the United States empagliflozin/linagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.

In the European Union empagliflozin/linagliptin is indicated in adults aged 18 years and older with type 2 diabetes mellitus:

• to improve glycemic control when metformin and/or sulphonylurea (SU) and empagliflozin or linagliptin do not provide adequate glycemic control;
• when already being treated with the free combination of empagliflozin and linagliptin.

Adverse effects

The most common side effects include urinary infections, nasopharyngitis, and upper respiratory tract infections . The most serious side effects include ketoacidosis (high blood levels of acids called ‘ketoacids’), pancreatitis (inflammation of the pancreas), hypersensitivity (allergic reactions) and hypoglycaemia (low blood sugar levels).

History

The combination preparation was developed and is marketed by Boehringer Ingelheim and Eli Lilly and Company under the brand name Glyxambi.

Further reading

• Kim ES, Deeks ED (September 2015). "Empagliflozin/Linagliptin: A Review in Type 2 Diabetes". Drugs. 75 (13): 1547–57. doi:10.1007/s40265-015-0457-z. PMID 26323340. S2CID 27675087.

External links

• "Empagliflozin mixture with linagliptin". Drug Information Portal. U.S. National Library of Medicine.